• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by EDAP TMS S.A. (Amendment)

    9/28/22 5:01:05 PM ET
    $EDAP
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $EDAP alert in real time by email
    SC 13G/A 1 d382632dsc13ga.htm SC 13G/A SC 13G/A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    (Amendment No. 2)*

     

     

    EDAP TMS S.A.

    (Name of Issuer)

    Ordinary Shares, nominal value €0.13 per share, in the form of American Depositary Shares

    (Title of Class of Securities)

    268311107

    (CUSIP Number)

    September 27, 2022

    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

      ☐

    Rule 13d-1(b)

     

      ☒

    Rule 13d-1(c)

     

      ☐

    Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP NO. 268311107

     

      1    

    NAMES OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    Soleus Capital Master Fund, L.P.

      2  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

    (a)  ☐        (b)  ☐

     

      3  

    SEC USE ONLY

     

      4  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Cayman Islands

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING PERSON

    WITH:

       5      

    SOLE VOTING POWER

     

    0

       6   

    SHARED VOTING POWER

     

    3,489,745 Ordinary Shares, nominal value €0.13 per share (“Ordinary Shares”) (represented by 3,489,745 American Depositary Shares (“ADS”)) (1)

       7   

    SOLE DISPOSITIVE POWER

     

    0

       8   

    SHARED DISPOSITIVE POWER

     

    3,489,745 Ordinary Shares (represented by 3,489,745 ADS) (1)

      9    

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    3,489,745 Ordinary Shares (represented by 3,489,745 ADS) (1)

    10  

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

    ☐

    11  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    9.5% (2)

    12  

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    FI

    FOOTNOTES

     

    (1)

    The securities reported in this row are held by Soleus Capital Master Fund, L.P. (“Master Fund”). Soleus Capital, LLC is the sole general partner of Master Fund and thus holds voting and dispositive power over the securities held by Master Fund. Soleus Capital Group, LLC is the sole managing member of Soleus Capital, LLC. Mr. Guy Levy is the sole managing member of Soleus Capital Group, LLC. Each of Soleus Capital Group, LLC, Soleus Capital, LLC and Mr. Guy Levy disclaims beneficial ownership of these securities held by Master Fund and this report shall not be deemed an admission that they are the beneficial owners of such securities for purposes of Section 13(d) of the Exchange Act, or for any other purpose, except to the extent of their respective pecuniary interests therein.

    (2)

    This percentage is calculated based upon 36,545,303 Ordinary Shares outstanding as of September 27, 2022, after giving effect to the public offering described in the Issuer’s prospectus supplement dated September 22, 2022 (and the exercise by the underwriters of the over-allotment in full).


    CUSIP NO. 268311107

     

      1    

    NAMES OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    Soleus Capital, LLC

      2  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

    (a)  ☐        (b)  ☐

     

      3  

    SEC USE ONLY

     

      4  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING PERSON

    WITH:

       5      

    SOLE VOTING POWER

     

    0

       6   

    SHARED VOTING POWER

     

    3,489,745 Ordinary Shares (represented by 3,489,745 ADS) (1)

       7   

    SOLE DISPOSITIVE POWER

     

    0

       8   

    SHARED DISPOSITIVE POWER

     

    3,489,745 Ordinary Shares (represented by 3,489,745 ADS) (1)

      9    

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    3,489,745 Ordinary Shares (represented by 3,489,745 ADS) (1)

    10  

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

    ☐

    11  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    9.5% (2)

    12  

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    OO

    FOOTNOTES

     

    (1)

    The securities reported in this row are held by Master Fund. Soleus Capital, LLC is the sole general partner of Master Fund and thus holds voting and dispositive power over the securities held by Master Fund. Soleus Capital Group, LLC is the sole managing member of Soleus Capital, LLC. Mr. Guy Levy is the sole managing member of Soleus Capital Group, LLC. Each of Soleus Capital Group, LLC, Soleus Capital, LLC and Mr. Guy Levy disclaims beneficial ownership of these securities held by Master Fund and this report shall not be deemed an admission that they are the beneficial owners of such securities for purposes of Section 13(d) of the Exchange Act, or for any other purpose, except to the extent of their respective pecuniary interests therein.

    (2)

    This percentage is calculated based upon 36,545,303 Ordinary Shares outstanding as of September 27, 2022.


    CUSIP NO. 268311107

     

      1    

    NAMES OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    Soleus Capital Group, LLC

      2  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

    (a)  ☐        (b)  ☐

     

      3  

    SEC USE ONLY

     

      4  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING PERSON

    WITH:

       5      

    SOLE VOTING POWER

     

    0

       6   

    SHARED VOTING POWER

     

    3,489,745 Ordinary Shares (represented by 3,489,745 ADS) (1)

       7   

    SOLE DISPOSITIVE POWER

     

    0

       8   

    SHARED DISPOSITIVE POWER

     

    3,489,745 Ordinary Shares (represented by 3,489,745 ADS) (1)

      9    

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    3,489,745 Ordinary Shares (represented by 3,489,745 ADS) (1)

    10  

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

    ☐

    11  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    9.5% (2)

    12  

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    OO

    FOOTNOTES

     

    (1)

    The securities reported in this row are held by Master Fund. Soleus Capital, LLC is the sole general partner of Master Fund and thus holds voting and dispositive power over the securities held by Master Fund. Soleus Capital Group, LLC is the sole managing member of Soleus Capital, LLC. Mr. Guy Levy is the sole managing member of Soleus Capital Group, LLC. Each of Soleus Capital Group, LLC, Soleus Capital, LLC and Mr. Guy Levy disclaims beneficial ownership of these securities held by Master Fund and this report shall not be deemed an admission that they are the beneficial owners of such securities for purposes of Section 13(d) of the Exchange Act, or for any other purpose, except to the extent of their respective pecuniary interests therein.

    (2)

    This percentage is calculated based upon 36,545,303 Ordinary Shares outstanding as of September 27, 2022.


    CUSIP NO. 268311107

     

      1    

    NAMES OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    Soleus Private Equity Fund III, L.P.

      2  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

    (a)  ☐        (b)  ☐

     

      3  

    SEC USE ONLY

     

      4  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING PERSON

    WITH:

       5      

    SOLE VOTING POWER

     

    0

       6   

    SHARED VOTING POWER

     

    1,400,000 Ordinary Shares, nominal value €0.13 per share (“Ordinary Shares”) (represented by 1,400,000 American Depositary Shares (“ADS”)) (1)

       7   

    SOLE DISPOSITIVE POWER

     

    0

       8   

    SHARED DISPOSITIVE POWER

     

    1,400,000 Ordinary Shares (represented by 1,400,000 ADS) (1)

      9    

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    1,400,000 Ordinary Shares (represented by 1,400,000 ADS) (1)

    10  

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

    ☐

    11  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    3.8% (2)

    12  

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    PN

    FOOTNOTES

     

    (1)

    The shares reported in this row are held by Soleus Private Equity Fund III, L.P. (“Soleus PE”). Soleus Private Equity GP III, LLC (“Soleus GP”) is the sole general partner of Soleus PE and thus holds voting and dispositive power over the shares held by Soleus PE. Soleus PE GP III, LLC is the sole manager of Soleus GP. Mr. Guy Levy is the sole managing member of Soleus PE GP III, LLC. Each of Soleus PE GP III, LLC, Soleus GP and Mr. Guy Levy disclaims beneficial ownership of the securities held by Soleus PE and this report shall not be deemed an admission that they are or were the beneficial owners of such securities for purposes of Section 13(d) of the Exchange Act or for any other purpose, except to the extent of their respective pecuniary interests therein.

    (2)

    This percentage is calculated based upon 36,545,303 Ordinary Shares outstanding as of September 27, 2022.


    CUSIP NO. 268311107

     

      1    

    NAMES OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    Soleus Private Equity GP III, LLC

      2  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

    (a)  ☐        (b)  ☐

     

      3  

    SEC USE ONLY

     

      4  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING PERSON

    WITH:

       5      

    SOLE VOTING POWER

     

    0

       6   

    SHARED VOTING POWER

     

    1,400,000 Ordinary Shares, nominal value €0.13 per share (“Ordinary Shares”) (represented by 1,400,000 American Depositary Shares (“ADS”)) (1)

       7   

    SOLE DISPOSITIVE POWER

     

    0

       8   

    SHARED DISPOSITIVE POWER

     

    1,400,000 Ordinary Shares (represented by 1,400,000 ADS) (1)

      9    

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    1,400,000 Ordinary Shares (represented by 1,400,000 ADS) (1)

    10  

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

    ☐

    11  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    3.8% (2)

    12  

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    OO

    FOOTNOTES

     

    (1)

    The shares reported in this row are held by Soleus PE. Soleus GP is the sole general partner of Soleus PE and thus holds voting and dispositive power over the shares held by Soleus PE. Soleus PE GP III, LLC is the sole manager of Soleus GP. Mr. Guy Levy is the sole managing member of Soleus PE GP III, LLC. Each of Soleus PE GP III, LLC, Soleus GP and Mr. Guy Levy disclaims beneficial ownership of the securities held by Soleus PE and this report shall not be deemed an admission that they are or were the beneficial owners of such securities for purposes of Section 13(d) of the Exchange Act or for any other purpose, except to the extent of their respective pecuniary interests therein.

    (2)

    This percentage is calculated based upon 36,545,303 Ordinary Shares outstanding as of September 27, 2022.


    CUSIP NO. 268311107

     

      1    

    NAMES OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    Soleus PE GP III, LLC

      2  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

    (a)  ☐        (b)  ☐

     

      3  

    SEC USE ONLY

     

      4  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING PERSON

    WITH:

       5      

    SOLE VOTING POWER

     

    0

       6   

    SHARED VOTING POWER

     

    1,400,000 Ordinary Shares, nominal value €0.13 per share (“Ordinary Shares”) (represented by 1,400,000 American Depositary Shares (“ADS”)) (1)

       7   

    SOLE DISPOSITIVE POWER

     

    0

       8   

    SHARED DISPOSITIVE POWER

     

    1,400,000 Ordinary Shares (represented by 1,400,000 ADS) (1)

      9    

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    1,400,000 Ordinary Shares (represented by 1,400,000 ADS) (1)

    10  

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

    ☐

    11  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    3.8% (2)

    12  

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    OO

    FOOTNOTES

     

    (1)

    The shares reported in this row are held by Soleus PE. Soleus GP is the sole general partner of Soleus PE and thus holds voting and dispositive power over the shares held by Soleus PE. Soleus PE GP III, LLC is the sole manager of Soleus GP. Mr. Guy Levy is the sole managing member of Soleus PE GP III, LLC. Each of Soleus PE GP III, LLC, Soleus GP and Mr. Guy Levy disclaims beneficial ownership of the securities held by Soleus PE and this report shall not be deemed an admission that they are or were the beneficial owners of such securities for purposes of Section 13(d) of the Exchange Act or for any other purpose, except to the extent of their respective pecuniary interests therein.

    (2)

    This percentage is calculated based upon 36,545,303 Ordinary Shares outstanding as of September 27, 2022.


    CUSIP NO. 268311107

     

      1    

    NAMES OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    Guy Levy

      2  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

    (a)  ☐        (b)  ☐

     

      3  

    SEC USE ONLY

     

      4  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING PERSON

    WITH:

       5      

    SOLE VOTING POWER

     

    0

       6   

    SHARED VOTING POWER

     

    4,889,745 Ordinary Shares (represented by 4,889,745 ADS) (1)

       7   

    SOLE DISPOSITIVE POWER

     

    0

       8   

    SHARED DISPOSITIVE POWER

     

    4,889,745 Ordinary Shares (represented by 4,889,745 ADS) (1)

      9    

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    4,889,745 Ordinary Shares (represented by 4,889,745 ADS) (1)

    10  

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

    ☐

    11  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    13.4% (2)

    12  

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    IN

    FOOTNOTES

     

    (1)

    1,400,000 of the shares reported in this row are held directly by Soleus PE and 3,489,745 of the shares are reported in this row are held directly by Master Fund. Soleus GP is the sole general partner of Soleus PE and thus holds voting and dispositive power over the securities held by Soleus PE. Soleus PE GP III, LLC is the sole manager of Soleus GP, and Mr. Guy Levy is the sole managing member of Soleus GP III, LLC. Soleus Capital, LLC is the sole general partner of Master Fund and thus holds voting and dispositive power over the securities held by Master Fund. Soleus Capital Group, LLC is the sole managing member of Soleus Capital, LLC, and Mr. Guy Levy is the sole managing member of Soleus Capital Group, LLC. Each of Soleus PE GP III, LLC, Soleus GP and Mr. Guy Levy disclaims beneficial ownership of the securities held by Soleus PE, and each of Soleus Capital Group, LLC, Soleus Capital, LLC and Mr. Guy Levy disclaims beneficial ownership of the securities held by Master Fund, and, in each case, this report shall not be deemed an admission that they are the beneficial owners of such securities for purposes of Section 13(d) of the Exchange Act, or for any other purpose, except to the extent of their respective pecuniary interests therein.

    (2)

    This percentage is calculated based upon 36,545,303 Ordinary Shares outstanding as of September 27, 2022.


    Item 1.

     

      (a)

    Name of Issuer

    EDAP TMS S.A.

     

      (b)

    Address of Issuer’s Principal Executive Offices

    Parc Activite La Poudrette Lamartine

    4/6 Rue du Dauphine

    69120 Vaulx-en-Velin, France

    Item 2.

     

      (a)

    Name of Person(s) Filing

    Soleus Capital Master Fund, L.P.

    Soleus Capital, LLC

    Soleus Capital Group, LLC

    Soleus Private Equity GP III, LLC

    Soleus Private Equity Fund III, L.P.

    Soleus PE GP III, LLC

    Guy Levy

     

      (b)

    Address of Principal Business Office or, if none, Residence

    Soleus Capital Master Fund, L.P.

    104 Field Point Road, 2nd Floor

    Greenwich, CT 06830

    Soleus Capital, LLC

    104 Field Point Road, 2nd Floor

    Greenwich, CT 06830

    Soleus Capital Group, LLC

    104 Field Point Road, 2nd Floor

    Greenwich, CT 06830

    Soleus Private Equity GP III, LLC

    104 Field Point Road, 2nd Floor

    Greenwich, CT 06830

    Soleus Private Equity Fund III, L.P.

    104 Field Point Road, 2nd Floor

    Greenwich, CT 06830

    Soleus PE GP III, LLC

    104 Field Point Road, 2nd Floor

    Greenwich, CT 06830

    Guy Levy

    c/o Soleus Capital Management, L.P

    104 Field Point Road, 2nd Floor

    Greenwich, CT 06830


      (c)

    Citizenship

    Soleus Capital Master Fund, L.P. – Cayman Islands

    Soleus Capital, LLC – Delaware

    Soleus Capital Group, LLC – Delaware

    Soleus Private Equity GP III, LLC – Delaware

    Soleus Private Equity Fund III, L.P. – Delaware

    Soleus PE GP III, LLC – Delaware

    Guy Levy – United States

     

      (d)

    Title of Class of Securities

    Ordinary Shares, nominal value €0.13 per share (“Ordinary Shares”), represented by American Depositary Shares (“ADS”), each of which represents one Ordinary Share.

     

      (e)

    CUSIP Number

    There is no CUSIP number assigned to the Ordinary Shares. CUSIP number 268311107 has been assigned to the ADS, which are quoted on the Nasdaq Global Market under the symbol “EDAP”.

     

    Item 3.

    If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

    (a)

       ☐    Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).

    (b)

       ☐    Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).

    (c)

       ☐    Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. ☐78c).

    (d)

       ☐    Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8).

    (e)

       ☐    An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);

    (f)

       ☐    An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);

    (g)

       ☐    A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);

    (h)

       ☐    A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

    (i)

       ☐    A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

    (j)

       ☐    A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J).

    (k)

       ☐    Group, in accordance with §240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution:

     

    Item 4.

    Ownership.

    Reference is made to Items 5 – 11 on the preceding pages of this Schedule 13G.

    As of September 27, 2022, Master Fund holds an aggregate of 3,489,745 Ordinary Shares (represented by 3,489,745 ADS), representing approximately 9.5% of the issued and outstanding Ordinary Shares as of such date. The foregoing percentage is calculated based upon 36,545,303 Ordinary Shares outstanding as of September 27, 2022, after giving effect to the public offering described in the Issuer’s prospectus supplement dated September 22, 2022 (and the exercise by the underwriters of the over-allotment in full).


    As the general partner of Master Fund, Soleus Capital, LLC may be deemed to have shared power to vote or to direct the vote and to dispose or to direct the disposition of the securities held by Master Fund. As the sole managing member of Soleus Capital, LLC, Soleus Capital Group, LLC may be deemed to have shared power to vote or to direct the vote and to dispose or to direct the disposition of the securities held by Master Fund. As the sole managing member of Soleus Capital Group, LLC, Mr. Guy Levy may be deemed to have shared power to vote or to direct the vote and to dispose or to direct the disposition of the securities held by Master Fund.

    As of September 27, 2022, Soleus PE holds an aggregate of 1,400,000 Ordinary Shares (represented by 1,400,000 ADS), representing approximately 3.8% of the issued and outstanding Ordinary Shares as of such date. The foregoing percentage is calculated based upon 36,545,303 Ordinary Shares outstanding as of September 27, 2022, after giving effect to the public offering described in the Issuer’s prospectus supplement dated September 22, 2022 (and the exercise by the underwriters of the over-allotment in full).

    As the sole general partner of Soleus PE, Soleus GP may be deemed to have shared power to vote or to direct the vote and to dispose or to direct the disposition of the securities held by Soleus PE. As the sole manager of Soleus GP, Soleus PE GP III, LLC may be deemed to have shared power to vote or to direct the vote and to dispose or to direct the disposition of the securities held by Soleus PE. As the sole managing member of Soleus PE GP III, LLC, Mr. Guy Levy may be deemed to have shared power to vote or direct the vote and to dispose or to direct the disposition of the securities held by Soleus PE.

    Neither the filing of this Schedule 13G nor any of its contents shall be deemed to constitute an admission that Mr. Levy, Soleus Capital, LLC, Soleus Capital Group, LLC, Soleus Private Equity GP III, LLC or Soleus PE GP III, LLC is the beneficial owner of the securities of the Issuer referred to herein for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, or for any other purpose, and such beneficial ownership is expressly disclaimed, except to the extent of their respective pecuniary interests therein.

     

    Item 5.

    Ownership of Five Percent or Less of a Class

    Not applicable.

     

    Item 6.

    Ownership of More than Five Percent on Behalf of Another Person.

    Not applicable.

     

    Item 7.

    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company

    Not applicable.

     

    Item 8.

    Identification and Classification of Members of the Group

    Not applicable.


    Item 9.

    Notice of Dissolution of Group

    Not applicable.

     

    Item 10.

    Certification

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose, or with the effect, of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.


    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, the undersigned certify that the information set forth in this statement is true, complete and correct.

     

    Date: September 28, 2022     Soleus Capital Master Fund, L.P.
        By:   Soleus Capital, LLC, its General Partner
        By:   Soleus Capital Group, LLC, its Managing Manager
        By:  

    /s/ Guy Levy

        Name:   Guy Levy
        Title:   Managing Member
    Date: September 28, 2022     Soleus Capital, LLC
        By:   Soleus Capital Group, LLC, its Managing Manager
        By:  

    /s/ Guy Levy

        Name:   Guy Levy
        Title:   Managing Member
    Date: September 28, 2022     Soleus Capital Group, LLC
        By:  

    /s/ Guy Levy

        Name:   Guy Levy
        Title:   Managing Member
    Date: September 28, 2022     Soleus Private Equity Fund III, L.P.
        By:   Soleus Private Equity GP III, LLC, its General Partner
        By:   Soleus PE GP III, LLC, its Manager
        By:  

    /s/ Guy Levy

        Name:   Guy Levy
        Title:   Managing Member
    Date: September 28, 2022     Soleus Private Equity GP III, LLC
        By:   Soleus PE GP III, LLC, its Manager
        By:  

    /s/ Guy Levy

        Name:   Guy Levy
        Title:   Managing Member


    Date: September 28, 2022     Soleus PE GP III, LLC
        By:  

    /s/ Guy Levy

        Name:   Guy Levy
        Title:   Managing Member
    Date: September 28, 2022    

    /s/ Guy Levy

        Name:   Guy Levy

    Footnotes:

     

    Attention:  Intentional

    misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001)

     

    Get the next $EDAP alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $EDAP

    DatePrice TargetRatingAnalyst
    4/4/2025$2.00Buy → Hold
    Jefferies
    11/1/2022$11.00Buy
    Jefferies
    11/19/2021$12.00 → $11.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $EDAP
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by EDAP TMS S.A.

      SC 13G/A - EDAP TMS SA (0001041934) (Subject)

      11/14/24 3:36:33 PM ET
      $EDAP
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SC 13G/A filed by EDAP TMS S.A. (Amendment)

      SC 13G/A - EDAP TMS SA (0001041934) (Subject)

      2/2/24 9:41:45 AM ET
      $EDAP
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SC 13G/A filed by EDAP TMS S.A. (Amendment)

      SC 13G/A - EDAP TMS SA (0001041934) (Subject)

      2/14/23 8:19:52 AM ET
      $EDAP
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $EDAP
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $EDAP
    SEC Filings

    See more
    • EDAP to Announce First Quarter 2025 Financial Results on May 15, 2025

      Company to host conference call and webcast on Thursday, May 15th at 8:30am EDT LYON, France, May 1, 2025 -- EDAP TMS SA (NASDAQ:EDAP) ("the Company"), the global leader in robotic energy-based therapies, today announced that it will release its financial results for the first quarter ended March 31, 2025, before the markets open on Thursday, May 15th, 2025. An accompanying conference call and webcast will be conducted by Ryan Rhodes, Chief Executive Officer, Ken Mobeck, Chief Financial Officer, and François Dietsch, Chief Accounting Officer. Please refer to the information below for conference call dial-in information and webcast registration. Call Details: Date:                Thursd

      5/1/25 7:00:00 AM ET
      $EDAP
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • EDAP Announces Positive Results from the FARP Randomized Controlled Trial Presented at the American Urological Association (AUA) Annual Meeting

      Final 3-year outcome of Focal Ablation versus Radical Prostatectomy (FARP) Randomized Controlled Trial (RCT) presented at 120th AUA Annual Meeting on Sunday, April 27, 2025. Study achieved its primary endpoint and demonstrated that the rate of treatment failure in the Focal Ablation (FA) group is non-inferior to that in the Radical Prostatectomy (RP) group at the final 36-month follow-up. AUSTIN, Texas, April 29, 2025 - EDAP TMS SA (NASDAQ:EDAP), the global leader in robotic energy-based therapies, announced the positive final results of the Focal Ablation Versus Radical Prostatectomy (FARP) Study, the first randomized controlled trial completed comparing ultrasound energy-based focal ablat

      4/29/25 7:00:00 AM ET
      $EDAP
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • EDAP To Launch New Focal One® i Robotic HIFU system at the Upcoming 120th American Urological Association (AUA) Annual Meeting

      Focal One i expands HIFUsion® patient-specific imaging compatibility to include PSMA PET, ExactVu™ Micro-Ultrasound, along with AI-driven and intelligent algorithms including Unfold AI™ and OnQ™ ProstateFocal One i extends HIFUsion capabilities to integrate Koelis® 3D biopsy maps and DynaCAD Urology datasetsFocal One i system will enable future capabilities including treatment streaming and recording, remote collaborative procedures and expanded clinical indications AUSTIN, Texas, April 24, 2025 - EDAP TMS SA (NASDAQ:EDAP), the global leader in robotic energy-based therapies, announced the launch of the new Focal One i system at the upcoming 120th American Urological Association (AUA) Annua

      4/24/25 7:00:00 AM ET
      $EDAP
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form 20-F filed by EDAP TMS S.A.

      20-F - EDAP TMS SA (0001041934) (Filer)

      3/27/25 4:31:02 PM ET
      $EDAP
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form 6-K filed by EDAP TMS S.A.

      6-K - EDAP TMS SA (0001041934) (Filer)

      3/27/25 7:41:18 AM ET
      $EDAP
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form 6-K filed by EDAP TMS S.A.

      6-K - EDAP TMS SA (0001041934) (Filer)

      3/3/25 7:10:48 AM ET
      $EDAP
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $EDAP
    Leadership Updates

    Live Leadership Updates

    See more
    • EDAP Appoints Joshua H. Levine to Board of Directors

      PDF Version AUSTIN, Texas, January 10, 2025 -- EDAP TMS SA (NASDAQ:EDAP) ("the Company" or "EDAP"), the global leader in robotic energy-based therapies, today announced the appointment of Joshua H. Levine to its Board of Directors.  "We are pleased to welcome Josh Levine to our Board of Directors," said Dr. Lance Willsey, Interim Chairman of the Board of EDAP TMS. "Josh brings a wealth of executive experience and a track record of growing shareholder value by focusing on transformative, high growth business strategies within the medical technology sector. As EDAP continues to grow the market for its leading Focal One   robotic HIFU platform, Josh will help shape our strategic vision and ex

      1/10/25 7:00:00 AM ET
      $EDAP
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • EDAP Appoints Fran Schulz to Board of Directors

      PDF Version LYON, France, July 8, 2024 -- EDAP TMS SA (NASDAQ:EDAP) ("the Company" or "EDAP"), the global leader in robotic energy-based therapies, today announced the appointment of Fran Schulz to its Board of Directors. "We are pleased to welcome Fran Schulz to our Board of Directors," said Marc Oczachowski, Chairman of the Board of EDAP TMS. "Fran brings a wealth of executive experience in the healthcare industry, and her expertise spans across a broad array of strategic finance and accounting functions. She also possesses an in-depth understanding of U.S. and international regulatory issues, which will further strengthen our Board's leadership as we continue to expand Focal One global

      7/8/24 7:00:00 AM ET
      $EDAP
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • EDAP Appoints New Executive Leaders to Strengthen Europe and Middle East Commercial Operations

      New appointments bring significant commercial experience with a focus on growing key strategic markets Expands executive leadership in growing disruptive, robotics-based capital equipment in both Urology and Gynecology therapeutic applications LYON, France, June 3, 2024 - EDAP TMS SA (NASDAQ:EDAP), the global leader in robotic energy-based therapies, today announced the appointments of Damien Desmedt and Alexander Fromm to further strengthen the Company's European and Middle Eastern commercial leadership. Mr. Desmedt has been appointed Vice President of Sales for Europe, Middle East, Africa, and India (EMEAI), and Mr. Fromm has been appointed General Manager for Switzerland and will

      6/3/24 8:00:00 AM ET
      $EDAP
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $EDAP
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • EDAP TMS SA downgraded by Jefferies with a new price target

      Jefferies downgraded EDAP TMS SA from Buy to Hold and set a new price target of $2.00

      4/4/25 8:36:35 AM ET
      $EDAP
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Jefferies initiated coverage on EDAP TMS SA with a new price target

      Jefferies initiated coverage of EDAP TMS SA with a rating of Buy and set a new price target of $11.00

      11/1/22 6:28:24 AM ET
      $EDAP
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • HC Wainwright & Co. reiterated coverage on Edap TMS with a new price target

      HC Wainwright & Co. reiterated coverage of Edap TMS with a rating of Buy and set a new price target of $11.00 from $12.00 previously

      11/19/21 7:01:21 AM ET
      $EDAP
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $EDAP
    Financials

    Live finance-specific insights

    See more
    • EDAP to Announce First Quarter 2025 Financial Results on May 15, 2025

      Company to host conference call and webcast on Thursday, May 15th at 8:30am EDT LYON, France, May 1, 2025 -- EDAP TMS SA (NASDAQ:EDAP) ("the Company"), the global leader in robotic energy-based therapies, today announced that it will release its financial results for the first quarter ended March 31, 2025, before the markets open on Thursday, May 15th, 2025. An accompanying conference call and webcast will be conducted by Ryan Rhodes, Chief Executive Officer, Ken Mobeck, Chief Financial Officer, and François Dietsch, Chief Accounting Officer. Please refer to the information below for conference call dial-in information and webcast registration. Call Details: Date:                Thursd

      5/1/25 7:00:00 AM ET
      $EDAP
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • EDAP Reports Record HIFU Fourth Quarter and Full-Year 2024 Results

                  Record full-year 2024 HIFU revenue of USD 25.7 million, an increase of 15.3% over full-year 2023Record Q4 2024 HIFU revenue of USD 9.3 million, an increase of 15.0% over Q4 2023U.S. Focal One HIFU procedures grew 51% on a year-over-year basis in 2024Focal One receives CE Mark for the treatment of deep infiltrating endometriosisRecent landmark HIFI study publication demonstrates positive outcomes with Focal One® Robotic HIFU versus surgery in the management of prostate cancerFirst patients treated in Phase I/II study evaluating Focal One Robotic HIFU for the treatment of Benign Prostatic Hyperplasia (BPH)Company to host conference call and webcast today, March 27th, at 8:30 a.m.

      3/27/25 7:10:00 AM ET
      $EDAP
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • EDAP to Announce Fourth Quarter and Full Year 2024 Financial Results on March 27, 2025

      Company to host conference call and webcast on Thursday, March 27th at 8:30am EDT AUSTIN, Texas, March 6, 2025 -- EDAP TMS SA (NASDAQ:EDAP) ("the Company"), the global leader in robotic energy-based therapies, today announced that it will release its financial results for the fourth quarter and full year ended December 31, 2024, before the markets open on Thursday, March 27th, 2025. An accompanying conference call and webcast will be conducted by Ryan Rhodes, Chief Executive Officer, Ken Mobeck, Chief Financial Officer, and François Dietsch, Chief Accounting Officer. Please refer to the information below for conference call dial-in information and webcast registration. Call Details: Da

      3/6/25 7:00:00 AM ET
      $EDAP
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care